Yuan K. Chen
1095 Jiefang Avenue
Wuhan, 430030, China
Wuhan, 430030, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
Journal: JAMA
Published: June 17, 2026
Prospective Multicenter Observational Study of Anlotinib in Advanced Non-Small Cell Lung Cancer: Real-World Evidence From China.
Journal: Thoracic cancer
Published: November 21, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.
Journal: Future oncology (London, England)
Published: October 30, 2025
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
Journal: The Lancet. Oncology
Published: July 02, 2025
Engineering stable cd-based metal-organic framework photocatalysts via ligand pre-metallization and polynuclear clusters: enhanced charge separation for ciprofloxacin degradation.
Journal: Journal of colloid and interface science
Published: June 03, 2025
Genetically engineered T cell membrane-camouflaged nanoparticles triggered cuproptosis for synergistic bladder cancer photothermal-immunotherapy.
Journal: Journal of nanobiotechnology
Published: February 06, 2025
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 26, 2024
Constructing Quasi-Single Ion Conductors by a β-Cyclodextrin Polymer to Stabilize Zn Anode.
Journal: Angewandte Chemie (International ed. in English)
Published: June 28, 2024
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation.
Journal: Experimental hematology & oncology
Published: June 25, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
Journal: Med (New York, N.Y.)
Published: June 06, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).
Journal: Cancer communications (London, England)
Published: March 08, 2024
Last Updated: 09/26/2026